Knight Therapeutics Inc. Receives Prestigious Gender Diversity Recognition
MONTREAL – Knight Therapeutics Inc. (TSX: GUD) is thrilled to share exciting news as it is honored on The Globe and Mail’s 2025 Report on Business magazine’s sixth annual Women Lead Here benchmark. This recognition highlights companies dedicated to enhancing executive gender diversity within Canada’s corporate landscape.
Commitment to Diversity and Inclusion
Samira Sakhia, President and CEO of Knight Therapeutics Inc., expressed immense pride in this achievement. She stated, “We are both proud and humble to have Knight Therapeutics once again recognized among top Canadian companies for executive gender diversity. A commitment to diversity is a fundamental aspect of our values, and we continually strive to foster these principles daily.”
Understanding the Women Lead Here Benchmark
Established in 2020, the Women Lead Here benchmark by the Report on Business magazine provides valuable insights into the gender dynamics of executive teams across Canadian corporations. The ranking evaluates companies based on a proprietary research methodology that compares the ratios of female to male executives in senior leadership positions.
Assessment Methodology
For this year's ranking, an analysis of around 500 publicly traded companies in Canada was carried out based on revenue metrics. The analysis aimed to ascertain the female-identifying to male-identifying executives' ratio among the top three tiers of leadership. The findings were then processed using a formula that also considered overall company performance, diversity initiatives, and progress over the years.
Gender Parity Achieved
A total of 93 companies earned the Women Lead Here recognition for 2025, reflecting a combined average of 46% of executive roles occupied by female-identifying leaders. This remarkable statistic signifies a transformative shift in executive roles across the corporate world.
About The Globe and Mail
The Globe and Mail holds a prominent position in Canada as the leading news media organization, fostering critical discussions and policy changes through independent journalism since 1844. Reaching millions through its print and digital platforms, the company has established a reputation for excellence in reporting across various sectors, including business and politics.
About Knight Therapeutics Inc.
Headquartered in Montreal, Knight Therapeutics Inc. is a leading specialty pharmaceutical company focused on acquiring, in-licensing, and commercializing pharmaceutical products across Canada and Latin America. Under its subsidiaries, such as United Medical, Biotoscana Farma, and Laboratorio LKM, the company aims to enhance the healthcare landscape in these regions. Knight trades on the TSX under the symbol GUD, and for more information, visit www.knighttx.com.
Frequently Asked Questions
What does the Women Lead Here benchmark evaluate?
The benchmark assesses executive gender diversity within top Canadian corporations, highlighting companies making notable progress toward gender parity in leadership roles.
How many companies were recognized in the 2025 report?
93 companies were acknowledged in the 2025 Women Lead Here report, with an average of 46% female-identifying individuals in executive positions.
Who is the President and CEO of Knight Therapeutics Inc.?
Samira Sakhia serves as the President and Chief Executive Officer of Knight Therapeutics Inc., leading the company's initiatives and values.
When was the Women Lead Here benchmark created?
The Women Lead Here benchmark was established in 2020 to identify companies excelling in executive gender diversity in Canada.
What is Knight Therapeutics Inc.'s main focus?
Knight Therapeutics Inc. specializes in acquiring and commercializing pharmaceutical products, particularly in Canada and Latin American markets.
